Aliases & Classifications for Somatization Disorder

MalaCards integrated aliases for Somatization Disorder:

Name: Somatization Disorder 12 74 15 71 32
Somatoform Disorders 44 32
Polysomatising Disorder 12
Somatisation Disorder 12
Somatoform Disorder 71
Briquet's Disorder 12

Classifications:



External Ids:

Disease Ontology 12 DOID:13918
ICD9CM 34 300.81
MeSH 44 D013001
SNOMED-CT 67 60368009
ICD10 32 F45 F45.0
UMLS 71 C0037650 C0520482

Summaries for Somatization Disorder

Disease Ontology : 12 A somatoform disorder that involves persistently complaints of varied physical symptoms that have no identifiable physical origin.

MalaCards based summary : Somatization Disorder, also known as somatoform disorders, is related to body dysmorphic disorder and depression, and has symptoms including multiple somatic complaints An important gene associated with Somatization Disorder is SLC6A4 (Solute Carrier Family 6 Member 4), and among its related pathways/superpathways are Signaling by GPCR and Sudden Infant Death Syndrome (SIDS) Susceptibility Pathways. The drugs Flunarizine and Cycloserine have been mentioned in the context of this disorder. Affiliated tissues include spinal cord, dorsal root ganglion and bone, and related phenotypes are Decreased nuclei size in G2M and cardiovascular system

Wikipedia : 74 Somatization disorder is a mental disorder characterized by recurring, multiple, and current, clinically... more...

Related Diseases for Somatization Disorder

Diseases related to Somatization Disorder via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 224)
# Related Disease Score Top Affiliating Genes
1 body dysmorphic disorder 31.0 SLC6A4 OXT
2 depression 30.6 SLC6A4 HTR1A CRH
3 conversion disorder 30.4 CRH COMT
4 personality disorder 30.3 SLC6A4 HTR1A CRH COMT
5 antisocial personality disorder 30.3 SLC6A4 OXT COMT
6 obsessive-compulsive personality disorder 30.3 SLC6A4 COMT
7 dissociative disorder 30.2 SLC6A4 OXT
8 generalized anxiety disorder 30.1 SLC6A4 HTR1A COMT
9 neurotic disorder 30.1 SLC6A4 POMC PCSK5 OXT IL6 HTR1A
10 somatoform disorder 30.1 TAC1 SLC6A4 IL6 CRH COMT
11 adjustment disorder 30.1 SLC6A4 POMC OXT HTR1A CRH
12 hypochondriasis 30.0 SLC6A4 POMC OXT HTR1A
13 bruxism 30.0 TAC1 SLC6A4 HTR1A COMT
14 drug dependence 29.9 SLC6A4 POMC CRH
15 social phobia 29.9 SLC6A4 OXT HTR1A CRH COMT
16 post-traumatic stress disorder 29.9 SLC6A4 POMC CRH COMT
17 complex regional pain syndrome 29.9 TAC1 POMC IL6
18 tobacco addiction 29.9 SLC6A4 CRH COMT
19 borderline personality disorder 29.8 SLC6A4 HTR1A CRH COMT
20 back pain 29.8 IL6 COMT
21 amnestic disorder 29.8 POMC OXT HTR1A
22 psychotic disorder 29.7 SLC6A4 OXT HTR1A COMT
23 agoraphobia 29.6 SLC6A4 HTR1A CRH COMT
24 alcohol use disorder 29.6 SLC6A4 HTR1A CRH COMT
25 constipation 29.6 TAC1 SLC6A4 IL6
26 eating disorder 29.6 SLC6A4 POMC CRH COMT
27 fibromyalgia 29.5 SLC6A4 POMC IL6 CRH COMT
28 phobia, specific 29.4 SLC6A4 OXT HTR1A CRH COMT
29 paine syndrome 29.4 TAC1 SLC6A4 IL6 COMT
30 postpartum depression 29.3 SLC6A4 OXT HTR1A CRH COMT
31 panic disorder 29.2 TAC1 SLC6A4 POMC HTR1A CRH COMT
32 alcohol dependence 29.2 SLC6A4 POMC HTR1A CRH COMT
33 acute stress disorder 29.1 SLC6A4 POMC OXT IL6 HTR1A CRH
34 chronic fatigue syndrome 29.1 SLC6A4 POMC IL6 HTR1A CRH COMT
35 bipolar disorder 29.0 SLC6A4 IL6 HTR1A CRH COMT
36 alexithymia 29.0 SLC6A4 OXT IL6 HTR1A COMT
37 phobic disorder 29.0 SLC6A4 POMC OXT HTR1A CRH COMT
38 substance abuse 29.0 SLC6A4 POMC IL6 HTR1A CRH COMT
39 dysthymic disorder 29.0 SLC6A4 POMC IL6 HTR1A CRH COMT
40 mood disorder 29.0 SLC6A4 POMC IL6 HTR1A CRH COMT
41 mental depression 28.9 SLC6A4 POMC OXT IL6 HTR1A CRH
42 irritable bowel syndrome 28.8 TAC1 SLC6A4 POMC IL6 HTR1A CRH
43 major depressive disorder 28.7 TAC1 SLC6A4 POMC OXT IL6 HTR1A
44 body mass index quantitative trait locus 11 28.6 POMC OXT IL6 HTR1A CRH COMT
45 endogenous depression 28.5 SLC6A4 POMC OXT IL6 HTR1A CRH
46 obsessive-compulsive disorder 28.4 SLC6A4 POMC OXT IL6 HTR1A CRH
47 anxiety 28.2 TAC1 SLC6A4 POMC OXT IL6 HTR1A
48 disease of mental health 27.8 TAC1 SLC6A4 POMC PCSK5 OXT IL6
49 autonomic dysfunction 10.3
50 animal phobia 10.3 SLC6A4 OXT

Comorbidity relations with Somatization Disorder via Phenotypic Disease Network (PDN): (show all 13)


Acute Cystitis Anxiety
Dependent Personality Disorder Dysthymic Disorder
Esophagitis Generalized Anxiety Disorder
Histrionic Personality Disorder Hypertension, Essential
Hypochondriasis Hypothyroidism
Irritable Bowel Syndrome Major Depressive Disorder
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Somatization Disorder:



Diseases related to Somatization Disorder

Symptoms & Phenotypes for Somatization Disorder

UMLS symptoms related to Somatization Disorder:


multiple somatic complaints

GenomeRNAi Phenotypes related to Somatization Disorder according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased nuclei size in G2M GR00096-A 8.8 MRPL34 SLC6A4 TAC1

MGI Mouse Phenotypes related to Somatization Disorder:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.76 COMT HTR1A IL6 OXT PCSK5 POMC
2 endocrine/exocrine gland MP:0005379 9.56 COMT CRH GRAP2 IL6 OXT PCSK5
3 renal/urinary system MP:0005367 9.17 COMT CRH IL6 OXT PCSK5 POMC

Drugs & Therapeutics for Somatization Disorder

Drugs for Somatization Disorder (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 275)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Flunarizine Approved Phase 4 52468-60-7 941361
2
Cycloserine Approved Phase 4 68-41-7 401 6234
3
Estradiol Approved, Investigational, Vet_approved Phase 4 50-28-2 5757
4
Medroxyprogesterone acetate Approved, Investigational Phase 4 71-58-9
5
Tibolone Approved, Investigational Phase 4 5630-53-5
6
Polyestradiol phosphate Approved Phase 4 28014-46-2
7
Amitriptyline Approved Phase 4 50-48-6 2160
8
Ketorolac Approved Phase 4 74103-06-3, 66635-83-4 3826
9
Cyclobenzaprine Approved Phase 4 303-53-7 2895
10
Ibuprofen Approved Phase 4 15687-27-1 3672
11
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
12
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
13
Triamcinolone Approved, Vet_approved Phase 4 124-94-7 31307
14
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
15
Citalopram Approved Phase 4 59729-33-8 2771
16
Vitamin A Approved, Nutraceutical, Vet_approved Phase 4 68-26-8, 11103-57-4 445354
17 Antitubercular Agents Phase 4
18 Antibiotics, Antitubercular Phase 4
19 Antimetabolites Phase 4
20 Antidepressive Agents, Tricyclic Phase 4
21 Adrenergic Agents Phase 4
22 Anti-Inflammatory Agents, Non-Steroidal Phase 4
23 Antirheumatic Agents Phase 4
24 Estradiol 17 beta-cypionate Phase 4
25 Contraceptive Agents Phase 4
26 Estradiol 3-benzoate Phase 4
27 Estrogens Phase 4
28 Contraceptives, Oral Phase 4
29 Contraceptive Agents, Male Phase 4
30 Anabolic Agents Phase 4
31 Antihypertensive Agents Phase 4
32 Androgen Antagonists Phase 4
33 Antineoplastic Agents, Hormonal Phase 4
34
Medroxyprogesterone Phase 4 520-85-4 10631
35 Estrogen Receptor Modulators Phase 4
36 Androgens Phase 4
37 Amitriptyline, perphenazine drug combination Phase 4
38 Ketorolac Tromethamine Phase 4
39 Cyclooxygenase Inhibitors Phase 4
40 Psychotropic Drugs Phase 4
41 Neurotransmitter Agents Phase 4
42 Antidepressive Agents Phase 4
43 Serotonin Uptake Inhibitors Phase 4
44 Anti-Arrhythmia Agents Phase 4
45 Sodium Channel Blockers Phase 4
46 Anesthetics Phase 4
47 Anesthetics, Local Phase 4
48 Diuretics, Potassium Sparing Phase 4
49 Hormones Phase 4
50 abobotulinumtoxinA Phase 4

Interventional clinical trials:

(show top 50) (show all 246)
# Name Status NCT ID Phase Drugs
1 A Pilot Study to Treat Emotional Disorders in Primary Care With Evidence-based Psychological Techniques: A Randomized Controlled Trial Completed NCT01903096 Phase 4 Primary Care Treatment As Usual
2 Treatment of Myofascial Pain Syndrome With Lidocaine Injection and Physical Therapy, Alone or in Combination: a Single-blind, Randomized, Controlled Clinical Trial. Completed NCT01250184 Phase 4 Lidocaine injection
3 Neurologic Signatures of Chronic Pain Disorders Completed NCT02747940 Phase 4 flunarizine and/or pregabalin
4 Brain Imaging-based Strategies for Treating Urological Chronic Pelvic Pain Syndrome (UCPPS) Pain Completed NCT02385266 Phase 4 D-Cycloserine;Placebo (for D-cycloserine)
5 The Impact of Different Hormone Therapy Regimens on Lower Urinary Tract Symptoms, Sexual Function and Psychosomatic Disorder Recruiting NCT01822288 Phase 4 Tibolone;Estradiol & medroxyprogesterone acetate
6 Trigger Point Injection for Myofascial Pain Syndrome in the Low Back (T-PIMPS): A Randomized Controlled Trial. Recruiting NCT04704297 Phase 4 Treatment of Myofascial Pain Syndrome in the low back. This intervention will be based on outcomes of the medications listed below.;Evaluation of functional ability using a patient centered functional score known as the Modified Oswestry Disability Index (MODI). The intervention will be based on outcomes of medications below.;Following up with participants 60-72 hours after treatment in the Emergency Department. This intervention will be based on outcomes of the medications listed below.
7 Botox (Botulinum Toxin A) as a Treatment for Chronic Male Pelvic Pain Syndrome: A Randomized Placebo Controlled Trial Terminated NCT00194623 Phase 4 Botulinum Toxin A (Botox)
8 Using Saline for Myofascial Pain Syndromes (USAMPS) Terminated NCT02120261 Phase 4 Normal Saline;Lidocaine Hydrochloride;Triamcinolone acetonide
9 Chronic Bladder Pain Syndrome in Women: Can Doxycycline Help? A Prospective, Randomised,Placebo-controlled, Double-blind Study Terminated NCT01879930 Phase 4 doxycycline;placebo
10 Sinusitis and Facial Pain Disorders Anti-Depression Trial Terminated NCT00754793 Phase 4 escitalopram;placebo
11 A Comparative Study of Epigastric Pain Syndrome and Postprandial Distress Syndrome in Personality, Helicobacter Pylori Infection, Gastric Emptying and Response to Lansoprazole Treatment Withdrawn NCT00673972 Phase 4
12 A Randomized, Placebo-controlled Multi-center Clinical Trial to Evaluate the Efficacy and Safety of Pregabalin for the Treatment of Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/CPPS) Unknown status NCT00371033 Phase 3 Pregabalin;Placebo
13 The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the Src Homology 2-containing Inositol-5'-Phosphatase 1 (SHIP1) Pathway in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period Unknown status NCT02858453 Phase 3 AQX-1125 100 mg;AQX-1125 200 mg;Placebo
14 Prospective, Double-blind, Randomised, Placebo-controlled, Cross-over Study to Investigate the Effect of Intravenous Immunoglobulins on Complex Regional Pain Syndrome (CRPS, M. Sudeck) Unknown status NCT00949065 Phase 3
15 Double-Blind Randomized Controlled Trial: Thoracic Sympathetic Block for the Treatment of Complex Regional Pain Syndrome I of the Upper Limb Unknown status NCT01612364 Phase 3
16 Treatment of Patients With Chronic Functional Disorders. A Randomized Controlled Trial of Specialized Treatment Compared to Usual Care. Completed NCT00132197 Phase 2, Phase 3
17 Treatment of Somatization in Primary Care Completed NCT00050583 Phase 3
18 Efficacy of a Biopsychosocial Treatment for Somatizing Patients Carried Out by the General Practitioner Completed NCT00130988 Phase 3
19 Treating Refractory Symptoms in Primary Care (Hypochondriasis: Diagnosis, Description and Medical Care) Completed NCT00368212 Phase 3
20 A 16-week Prospective Randomised Double-blind Study on Facilitation of DYSPORT® Effect on Myofascial Pain Syndrome (MPS) by Electrical Stimulation. Completed NCT00246142 Phase 3
21 Dysfunctional Illness-related Cognitions in Individuals With Hypochondriasis and Change Thereof Completed NCT01119469 Phase 3
22 Multicenter, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Lenalidamide in the Treatment of Complex Regional Pain Syndrome Type1 Completed NCT00166452 Phase 3 Lenalidamide
23 Pharmacotherapy Relapse Prevention in Body Dysmorphic Disorder Completed NCT00149799 Phase 3 Escitalopram;Placebo
24 Phase 3 Study of a Standardized Pollen Extract Preparation (Cernilton) in Patients With Inflammatory Chronic Prostatitis-chronic Pelvic Pain Syndrome Completed NCT00919893 Phase 3 Cernilton;Placebo
25 A Verification Study of JNS020QD in Patients With Post-herpetic Neuralgia, Complex Regional Pain Syndrome (CRPS) or Postoperative Pain Syndrome Completed NCT01008553 Phase 3 Fentanyl;Placebo
26 Pain Exposure Physical Therapy Or Conservative Therapy for Patients With Complex Regional Pain Syndrome Type I Completed NCT00817128 Phase 2, Phase 3
27 Effectiveness of Diacutaneous Fibrolysis Technique on Pain, Range of Motion, Strength and Function in Patients With Patellofemoral Pain Syndrome Completed NCT02379364 Phase 3
28 Role of Vitamin C at 6 Months on Incidence of Complex Regional Pain Syndrome Type I in Upper Limb Surgery Recruiting NCT02390505 Phase 3 Vitamin C;Placebo
29 Treatment of Myofascial Pain Syndrome With Lidocaine Injection in Patients With Cancer in Palliative Care: a Randomized Clinical Trial Recruiting NCT04703803 Phase 3
30 Comparison of Botulinum Toxin Versus Placebo Injections to Temporalis and Masseter Muscles in the Management of Myofascial Pain Disorder: A Randomized Clinical Trial Recruiting NCT03223298 Phase 3 Botulinum toxin type A;0.9% Sodium Chloride Injection
31 A Prospective Randomized Study Comparing the Outcome of Electrical Stimulation of Vastus Medialis Obliquus Muscle and Physical Therapy vs Only Physical Therapy But no Electrical Stimulation in Patients With Patellofemoral Pain Syndrome Recruiting NCT03184545 Phase 3
32 A Prospective Randomized Controlled Pilot Study Nitrous Oxide for the Treatment of Complex Regional Pain Syndrome Enrolling by invitation NCT03879538 Phase 3 Nitrous Oxide;Oxygen
33 Pilot Study to Evaluate the Effectiveness of a Mixture of Ketamine / Lidocaine Administered by Mesotherapy in the Management of Neuropathic Pain in Complex Regional Pain Syndrome Type 1 (CRPS1). A Monocentric Randomized and Controlled Clinical Study Not yet recruiting NCT04650074 Phase 2, Phase 3 LIDOCAINE 20 mg;LIDOCAINE 20 mg + KETAMINE 20 mg;LIDOCAINE 20 mg + KETAMINE 40 mg
34 Placebo-controlled Efficacy and Safety Trial of Intravenous Neridronic Acid in Subjects With Complex Regional Pain Syndrome (CRPS) Terminated NCT03560986 Phase 3 Neridronic acid 100 mg;Placebo
35 Injection of Botulinum Toxin Type A Into the External Urethral Sphincter for Male Patients Suffering From Chronic Prostatitis/Chronic Pelvic Pain Syndrome (NIH Cat. III): a Prospective, Double-blind and Placebo-controlled Clinical Trial Terminated NCT00464373 Phase 3 Botulinum Toxin Type A;Placebo
36 Pharmacovigilance in Gerontopsychiatric Patients Terminated NCT02374567 Phase 3 Phenobarbital;Phenytoin;Carbamazepine;Oxcarbazepine;Valproic Acid;Lamotrigine;Topiramate;Gabapentin;Levetiracetam;Pregabalin;Lacosamide;Clonazepam;Biperiden;Levomepromazine;Fluphenazine;Perphenazine;Perazine;Thioridazine;Haloperidol;Melperone;Pipamperone;Bromperidol;Benperidol;Sertindole;Ziprasidone;Flupentixol;Chlorprothixene;Zuclopenthixol;Fluspirilene;Pimozide;Clozapine;Olanzapine;Quetiapine;Sulpiride;Tiapride;Amisulpride;Prothipendyl;Risperidone;Aripiprazole;Paliperidone;Diazepam;Oxazepam;Lorazepam;Bromazepam;Clobazam;Alprazolam;Hydroxyzine;Buspirone;Chloral Hydrate;Flurazepam;Nitrazepam;Triazolam;Lormetazepam;Temazepam;Midazolam;Brotizolam;Zopiclone;Zolpidem;Zaleplon;Melatonin;Clomethiazole;Diphenhydramine;Promethazine;Imipramine;Clomipramine;Opipramol;Trimipramine;Amitriptyline;Nortriptyline;Doxepin;Maprotiline;Amitriptyline oxide;Fluoxetine;Citalopram;Paroxetine;Sertraline;Fluvoxamine;Escitalopram;Tranylcypromine;Moclobemide;Mianserin;Trazodone;Mirtazapine;Bupropion;Venlafaxine;Reboxetine;Duloxetine;Agomelatine;Pyritinol;Piracetam;Donepezil;Rivastigmine;Galantamine;Memantine;Nicergoline;Acamprosate;Lithium
37 Intra-articular Hyaluronic Acid Injection for Therapy-resistant Patellofemoral Pain Syndrome: an Open-label, Randomized, Delayed-start Clinical Trial Unknown status NCT02613247 Phase 2
38 Phase 2 Study - The Use of a Single 5 mg Dose of Zoledronic Acid in Complex Regional Pain Syndrome Patient. Unknown status NCT01788176 Phase 2 Zoledronic acid;Placebo
39 Cognitive Behavior Therapy for Somatization Disorder Completed NCT00276887 Phase 2
40 Treatment of Multi-organ Bodily Distress Syndrome. A Double-blinded Placebo Controlled Trial of the Effects of Imipramine (Stress-3) Completed NCT01518634 Phase 2 Imipramine treatment;Placebo
41 Cognitive Affective Behavior Therapy for Somatization Completed NCT00149760 Phase 2
42 Treatment for Patellofemoral Pain Syndrome Using Knee Abduction Moment-Reducing Footwear Completed NCT01332110 Phase 1, Phase 2
43 A Phase II Multicentre Multinational Prospective Randomised Double-blind Placebo-controlled Study Assessing the Efficacy and Safety of a Single Application of Three Doses of Dysport® in Patients With Upper Back Myofascial Pain Syndrome Completed NCT00134810 Phase 2
44 An Open-Label Study of CC-10004 for Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT00701311 Phase 2 CC-10004
45 A Multicenter, Open-Label Study to Evaluate the Preliminary Safety and Efficacy of CC-5013 in the Treatment of Complex Regional Pain Syndrome (CRPS) Completed NCT00067743 Phase 2 Lenalidomide
46 A Multi-Center, Double-Blind, Placebo-Controlled Investigation of Silodosin in the Treatment of Subjects With Moderate to Severe Abacterial Chronic Prostatitis/Chronic Pelvic Pain Syndrome Completed NCT00740779 Phase 2 Silodosin 8 mg;Placebo;Silodosin 4 mg
47 Evaluation of the Effects of a Body-centered Emotional Stimulation in Healthy Persons Completed NCT01187797 Phase 1, Phase 2
48 Quadriceps Femoris Strengthening Versus Hamstring Stretching for Patellofemoral Pain Syndrome: A Randomized Clinical Trial. Completed NCT01691170 Phase 1, Phase 2
49 A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel-group, Proof of Concept Study to Investigate Efficacy, Safety, Pharmacodynamics and Pharmacokinetics of ASP6294 in the Treatment of Female Subjects With Bladder Pain Syndrome/Interstitial Cystitis Completed NCT03282318 Phase 2 ASP6294;Placebo
50 A Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of TAK-935 as an Adjunctive Therapy in Adult Subjects With Chronic Complex Regional Pain Syndrome Completed NCT03990649 Phase 2 TAK-935;TAK-935 Placebo

Search NIH Clinical Center for Somatization Disorder

Cochrane evidence based reviews: somatoform disorders

Genetic Tests for Somatization Disorder

Anatomical Context for Somatization Disorder

MalaCards organs/tissues related to Somatization Disorder:

40
Spinal Cord, Dorsal Root Ganglion, Bone, Brain, Cortex, Eye, Pituitary

Publications for Somatization Disorder

Articles related to Somatization Disorder:

(show top 50) (show all 1986)
# Title Authors PMID Year
1
Structural neuroimaging of somatoform disorders: A systematic review. 61
33359097 2021
2
Frequency-specific alterations of the frontal-cerebellar circuit in first-episode, drug-naive somatization disorder. 61
33221718 2021
3
Orthorexic eating behavior in patients with somatoform disorders. 61
31833044 2021
4
Peripandemic psychiatric emergencies: impact of the COVID-19 pandemic on patients according to diagnostic subgroup. 61
33544227 2021
5
Somatic symptoms following sexual assault in adolescents: a prospective longitudinal study. 61
33573390 2021
6
Suicide risk within 1 year of dementia diagnosis in older adults: a nationwide retrospective cohort study. 61
33119492 2021
7
The relationship of cortical activity induced by pain stimulation with clinical and cognitive features of somatic symptom disorder: A controlled functional near infrared spectroscopy study. 61
33248397 2021
8
Symptoms within somatization after sexual abuse among women: A scoping review. 61
33423277 2021
9
[Improvement of Mental Health and Bonding in Women with Mental Disorders in the Postpartum Period - Evaluation of an Interaction-Centered Treatment of a Mother-Baby Day Clinic]. 61
33440450 2021
10
Managing mental health on a prolonged deployment: UK military exercise SAIF SAREEA 3. 61
32474439 2020
11
A retrospective observational study comparing somatosensory amplification in fibromyalgia, chronic pain, psychiatric disorders and healthy subjects. 61
33130631 2020
12
Common mental disorders among patients attending monk healers and primary health care centres in Thailand: a cross-sectional study. 61
33292410 2020
13
Life satisfaction in persons with mental disorders. 61
32556822 2020
14
Psychotherapists' perspective on the treatment of patients with somatic symptom disorders. 61
32896756 2020
15
An age-period-cohort analysis for prevalence of common psychiatric disorders in Japan, 1999-2017. 61
33221927 2020
16
The case for improved transdiagnostic detection of first-episode psychosis: Electronic health record cohort study. 61
33234425 2020
17
Parental income as a marker for socioeconomic position during childhood and later risk of developing a secondary care-diagnosed mental disorder examined across the full diagnostic spectrum: a national cohort study. 61
33190641 2020
18
[The Pathological Buying Screener: Validation in a Clinical Sample]. 61
33246347 2020
19
C-Reactive Protein as a Possible Predictor of Trail-Making Performance in Individuals with Psychiatric Disorders. 61
33023087 2020
20
Anxiety is the cause of the worse outcomes of allergic patients after total knee arthroplasty. 61
31722034 2020
21
A comparison of patients with somatic symptom disorder attending psychiatric services and those unwilling to attend psychiatric services. 61
32474346 2020
22
Changes in brain glucose metabolism and connectivity in somatoform disorders: an 18F-FDG PET study. 61
31720787 2020
23
[Mental Health and COVID-19 in children and adolescents: psychopathologycal and Public Health approach.] 61
33063746 2020
24
Nature and prevalence of combinations of mental disorders and their association with excess mortality in a population-based cohort study. 61
32931098 2020
25
Research output on mental health problems in North Korea between 2006 and 2017: A bibliographic analysis of North Korean medical journal articles. 61
32593086 2020
26
Abnormal Functional Asymmetry in the Salience and Auditory Networks in First-episode, Drug-naive Somatization Disorder. 61
32738433 2020
27
Increased prevalence of depression, anxiety, and adjustment and somatoform disorders in transsexual individuals. 61
32663979 2020
28
Multidisciplinary Management of Chronic Tinnitus in Audiophonology Centre: Survey of Psychiatric Comorbidities and Psychotropic Medications Use Over 10 Years of Activity. 61
32890358 2020
29
Behavioural modification interventions for medically unexplained symptoms in primary care: systematic reviews and economic evaluation. 61
32975190 2020
30
Evolution of bodily distress disorders. 61
32701520 2020
31
Mental illnesses and related vulnerabilities in the Hijra community: A cross-sectional study from India. 61
32815441 2020
32
The Impact of Impulsivity and Emotional Dysregulation on Comorbid Bipolar Disorder and Borderline Personality Disorder. 61
32923187 2020
33
Association of Domestic Violence Against Women With Sociodemographic Factors, Clinical Features, and Dissociative Symptoms in Patients Who Receive Services From Psychiatric Outpatient Units in Turkey. 61
29294725 2020
34
The Acceptability and Usability of Digital Health Interventions for Adults With Depression, Anxiety, and Somatoform Disorders: Qualitative Systematic Review and Meta-Synthesis. 61
32628116 2020
35
Somatization disorder mediates the association of depression and anxiety with functional impairment in patients with heart failure. 61
32703019 2020
36
Prospective pilot study to identify psychological factors influencing peri-operative pain in total knee arthroplasty (TKA). 61
32266414 2020
37
[The classification of dissociative disorders and bodily distress disorder: A comparison of ICD-10 and ICD-11]. 61
32667856 2020
38
Treatment of somatic symptom disorder in childhood: evidence-based psychotherapy interventions 61
32516123 2020
39
Comorbidities of Patients with Functional Somatic Syndromes Before, During and After First Diagnosis: A Population-based Study using Bavarian Routine Data. 61
32555301 2020
40
DEPRESSION IN THE STRUCTURE OF SOMATOFORM DISORDERS IN CHILDREN, ITS SIGNIFICANCE, THE ROLE OF SEROTONIN AND TRYPTOPHANE IN THE EMERGENCE OF THESE DISORDERS. 61
32841196 2020
41
[The role of the general practitioner in management of psychiatric disorders]. 61
32475623 2020
42
Determinants of Suicidality in the European General Population: A Systematic Review and Meta-Analysis. 61
32526975 2020
43
Mental Disorders and Suicide Risk among Cancer Patients: A Nationwide Cohort Study. 61
32538322 2020
44
Somatic Symptom Disorder, Medically Unexplained Symptoms, Somatoform Disorders, Functional Neurological Disorder: How DSM-5 Got It Wrong. 61
32191123 2020
45
Psychiatric characteristics of older persons with medically unexplained symptoms: A comparison with older patients suffering from medically explained symptoms. 61
32431253 2020
46
Psychiatric Morbidities of Elderly Out-patients Attending Various Outreach Clinics in Gandaki Province of Nepal: A Descriptive Cross-sectional Study. 61
32538926 2020
47
Parent-youth conflict as a predictor of depression in adulthood: a 15-year follow-up of a community-based cohort. 61
31302772 2020
48
Incidence of and factors associated with manic episodes and bipolar disorder in the decade following depression onset in Germany. 61
32056923 2020
49
The Influence of Socio-Demographic Factors, Lifestyle and Psychiatric Indicators on Adherence to Treatment of Patients with Rheumatoid Arthritis: A Cross-Sectional Study. 61
32295226 2020
50
Diagnostic Distribution of Psychiatric Disorders among Korean Young Adults. 61
32595346 2020

Variations for Somatization Disorder

Expression for Somatization Disorder

Search GEO for disease gene expression data for Somatization Disorder.

Pathways for Somatization Disorder

GO Terms for Somatization Disorder

Cellular components related to Somatization Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 secretory granule GO:0030141 8.8 POMC PCSK5 OXT

Biological processes related to Somatization Disorder according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 cell-cell signaling GO:0007267 9.71 TAC1 POMC PCSK5 GRAP2
2 associative learning GO:0008306 9.51 TAC1 CRH
3 vasoconstriction GO:0042310 9.49 SLC6A4 HTR1A
4 positive regulation of ossification GO:0045778 9.48 TAC1 OXT
5 positive regulation of renal sodium excretion GO:0035815 9.46 TAC1 OXT
6 positive regulation of acute inflammatory response GO:0002675 9.43 TAC1 IL6
7 sperm ejaculation GO:0042713 9.37 SLC6A4 OXT
8 response to ether GO:0045472 9.32 OXT CRH
9 positive regulation of corticosterone secretion GO:2000854 9.26 TAC1 CRH
10 female pregnancy GO:0007565 9.26 PCSK5 OXT CRH COMT
11 regulation of serotonin secretion GO:0014062 9.16 HTR1A CRH
12 response to pain GO:0048265 8.8 TAC1 CRH COMT

Molecular functions related to Somatization Disorder according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 neuropeptide hormone activity GO:0005184 9.16 OXT CRH
2 hormone activity GO:0005179 9.13 POMC OXT CRH
3 serotonin binding GO:0051378 8.62 SLC6A4 HTR1A

Sources for Somatization Disorder

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....